- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Policy Roundup for March 2023—Podcast Edition
On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Show notes
Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy
Policy Recommendations for Improving Biosimilar Uptake in Belgium
Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies
The Increasing Access to Biosimilars Act of 2023 Introduced to Congress
Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching
Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
